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Abstract
Exposure to arsenic in drinking water is associated with increased prevalence of diabetes. We
previously reported an association of diabetes and urinary concentration of dimethylarsinite
(DMAsIII), a toxic product of arsenic methylation by arsenic ( +3 oxidation state)
methyltransferase (AS3MT). Here we examine associations between AS3MT polymorphism,
arsenic metabolism and diabetes. Fasting blood glucose, oral glucose tolerance and self-reported
diagnoses were used to identify diabetic individuals. Inorganic arsenic and its metabolites were
measured in urine. Genotyping analysis focused on six polymorphic sites of AS3MT. Individuals
with M287T and G4965C polymorphisms had higher levels of urinary DMAsIII and were more
frequently diabetic than the respective wild-type carriers, although the excess was not statistically
significant. Odds ratios were 11.4 (95% confidence interval (CI) 2.2–58.8) and 8.8 (95% CI 1.6–
47.3) for the combined effects of arsenic exposure >75th percentile and 287T and 4965C
genotypes, respectively. Carriers of 287T and 4965C may produce more DMAsIII and be more
likely to develop diabetes when exposed to arsenic.
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Chronic exposure to inorganic arsenic (iAs) in drinking water has been associated with
cancer and it is suspected to cause other chronic diseases, including diabetes.1 There is,
however, a high degree of inter-individual variation in iAs metabolism and disease
manifestation. Arsenic ( + 3 oxidation state) methyltransferase (AS3MT) is the key enzyme
in the pathway for the methylation of iAs.2 AS3MT polymorphism has been shown to
account in part for inter-individual differences in iAs metabolism. The presence of variant
alleles in intronic G12390C (rs3740393), C14215T (rs3740390) and G35991A (rs10748835)
SNPs were shown to be significantly associated with the second methylation step in
indigenous women in northern Argentina, that is, with lower percentage of total As (tAs) in
urine represented by monomethylarsenic (MAs) and higher percentage represented by
dimethylarsenic (DMAs). These polymorphisms were in a strong linkage and with higher
allelic frequencies than those previously reported for other populations.3 In addition,
variation in the percentage of MAs in urine was linked to the presence of rs3740393 SNP in
AS3MT gene and to individual cancer susceptibility.4 A lower percentage of DMAs and a
lower DMAs/ MAs ratio was detected in urine of Vietnamese carriers of variant alleles for
G35991A (rs10748835) SNP in AS3MT.5,6 Multiple studies showed that the most common
exonic AS3MT SNP Met287Thr (rs11191439) is associated with higher percentage of MAs
in urine of subjects exposed to iAs.7,8 In addition, iAs-exposed carriers of the
AS3MT(Met287Thr) variant have increased prevalence of DNA damage and skin lesions
characteristic of iAs exposure.9,10 Wood and associates reported differences in variable
number of tandem repeats (VNTRs) in 5’-UTR region of AS3MT: transfection of HepG2
cells with a reporter gene constructs containing the VNTR variants (AB, A2B and A3B)
indicated that the shorter VNTR (AB) was associated with higher activity of the reporter
gene.11
To investigate the role of AS3MT polymorphism in the metabolism of iAs and the
development of diabetes, we conducted a cross-sectional study in the Zimapan and Lagunera
regions in Mexico where levels of iAs in ground water were historically high. We focused
on variation in the production of toxic methylated trivalent metabolites of iAs,
methylarsonite (MAsIII) and dimethylarsinite (DMAsIII) and associations of diabetes
indicators with AS3MT polymorphism. Six polymorphic sites (G12390C, rs3740393;
C14215T, rs3740390; G35991A, rs10748835; Met287Thr, rs11191439; G4965C,
rs17881215; VNTR) previously linked to differences in iAs metabolism or susceptibility to
iAs toxicity11–16 were examined.
MATERIALS AND METHODS
Details of population recruitment, data collection and analytical methods have been
published elsewhere.17 Briefly, we recruited individuals ≥5 years old who had resided in
either region for ≥2 years and those giving consent were invited for an interview during
which they completed a questionnaire on consumption and sources of drinking water, health
history and potential occupational exposures to arsenic. Pregnant women, alcoholics and
individuals with urinary tract diseases or occupational exposures to arsenic were excluded.
Eligible subjects provided a sample of the water typically used for drinking at home and a
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spot urine sample. Fasting blood was collected, followed by oral glucose tolerance test
(OGTT) and sampling of venous blood 2 h after glucose administration. Body weight,
height, blood pressure and waist-to-hip ratio were also recorded. All procedures involving
human subjects were approved by Institutional Review Boards of Cinvestav-IPN and
University of North Carolina at Chapel Hill.
The concentrations of iAs in drinking water and tAs in urine was determined by hydride
generation-atomic fluorescence spectrometry18 after acid digestion.19 The concentration of
iAs in water was expressed in ng As/ml or p.p.b.; tAs concentration in urine was expressed
in ng As/ml. Hydride generation-cryotrapping-atomic absorption spectrometry was used for
the oxidation state-specific analysis of iAs metabolites in urine.20,21 To limit oxidation of
unstable MAsIII and DMAsIII, aliquots of freshly collected urines were frozen in dry ice and
analyzed within 6 h after collection. We have shown that only ~10% of DMAsIII, the most
unstable metabolite of iAs, oxidizes in human urine under these conditions.17 Pentavalent
arsenicals were analyzed in aliquots of urine that were stored at −80 °C. Concentrations of
arsenic species in urine were expressed in ng As/ml. Values of MAsIII and DMAsIII that
were below the limit of detection (LOD) of 0.1 ng As/ml were replaced with LOD/21/2 for
statistical analysis.
Glucose concentrations were determined in the fasting and 2-h blood samples, using
calibrated HemoCue Glucose 201RT glucometer (HemoCue, Lake Forest, CA, USA) that
reports results in plasma glucose equivalent values. Subjects were classified as having
diabetes if they had any of the following: fasting blood glucose level (FBG) ≥126 mg/dl, 2-h
blood glucose level determined by OGTT (2HBG) ≥200 mg/dl, self-reported doctor
diagnosis of diabetes or use of anti-diabetic medication.
DNA was isolated from blood using QIAamp DNA Blood Mini Kit (Qiagen) according to
the manufacturer’s protocol. The AS3MT single-nucleotide polymorphisms were analyzed
in the Mammalian Genotyping Core (UNC, Chapel Hill, NC, USA), using predesigned or
custom TaqMan assays (Applied Biosystems, Carlsbad, CA, USA). The ABI Dual 384-Well
GeneAmp PCR System 9700 and ABI PRISM 7900HT Sequence Detection System from
Applied Biosystems was used for genotyping and the ABI SDS software for data analysis.
The VNTR variants (AB, A2B and A3B) and G4965C polymorph were identified by
sequencing of a PCR-amplified promoter region.22 For quality control, 10% of DNA
samples were re-analyzed. The re-analysis found no systematic errors.
Associations of iAs and its metabolites in urine and of continuous variables for diabetes
markers (2HBG and FBG) with AS3MT genotypes were analyzed by multiple linear
regression. All continuous variables were approximately log-normally distributed, so log
transformations were used. Associations of diabetes status with genotype were examined
using logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs).
Age in years, sex, hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood
pressure ≥90 mm Hg or reported use of anti-hypertensive drugs) and obesity (BMI>30
kg/m2) were included as covariates in models for diabetes and diabetes markers. No
adjustment was made for urinary creatinine because of indications that creatinine
concentration is associated with both diabetes status and the efficiency of iAs
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methylation.23–25 Interactions between AS3MT polymorphism and iAs exposure were
examined in analyses of the separate and combined effects of genotype and iAs
concentration >75th percentile of the exposure distribution (52 p.p.b.). Statistical analyses
were performed in Stata version 11.2 for Mac OS X (StataCorp, College Station, TX, USA).
RESULTS
We enrolled 255 individuals with information on AS3MT SNPs (171 females and 84 males)
in total. Data on G12390C, C14215T and G4965C SNPs and VNTR structure were not
available for all participants. Characteristics of the population and genotype frequencies are
given in Table 1. All SNPs were in Hardy– Weinberg equilibrium (Table 1). Two pairs of
SNPs, M287T and G4965C, C14215T and G12390C were in linkage disequilibrium with
r2>0.7 (Supplementary eTable 1).
The concentrations of MAsIII and DMAsIII in urine were elevated in individuals with variant
M287T (TC + CC) and G4965C (GC + CC) genotypes compared with the respective wild-
type (TT and GG) carriers (Table 2). The effects of these genotypes on DMAsIII were more
pronounced than on MAsIII. In contrast, the levels of both MAsIII and DMAsIII were
reduced in individuals with the variant genotypes of G35991A, and the level of MAsIII was
also reduced in individuals with variant VNTR A2B (Table 2). When diabetes markers were
analyzed as continuous variables, carriers of the M287T (TC + CC) and G4965C (GC + CC)
genotypes had elevated levels of 2HBG and FBG compared with individuals with the wild-
type genotypes (Table 2). There was little indication of consistent association of any other
genotype with diabetes (data not shown) or with 2HBG or FBG (Table 2). The VNTR–A2B
structure was, however, associated with higher DMAs/MAs ratio (β 1.17, 95% CI 0.2–2.3).
A3B structure was not found.
Individuals with the C allele in M287T or G4965C were also more likely to be classified as
diabetic than the wild-type carriers: OR 2.70 (95% CI 0.93–7.80) and OR 2.24 (95% CI
0.69–7.25), respectively, although the associations did not reach the conventional level of
statistical significance. Other polymorphisms were less strongly associated with diabetes and
the ORs were more imprecise (Table 3). We repeated the analysis for G35991A using a co-
dominant model with AG located midway between AA and GG. The resulting ORs were
0.88 (95% CI 0.53–1.44) for AG and 0.77 (95% CI 0.21–2.82) for GG. ORs based on
classification of diabetes using only 2HBG ≥200 mg/dl or FBG ≥126 mg/dl in addition to
self-reported diagnosis or medication use were similar in magnitude and precision
(Supplementary eTables 2 and 3).
Analyses of the interaction of M287T genotype and exposure to iAs in drinking water
(Figure 1) suggested increasing associations of diabetes with variant (TC + CC) genotype
and exposure at >75th percentile of concentration (52 p.p.b.) separately (ORs 3.47 and 5.68,
respectively) and in combination (OR 11.41). The pattern of separate and combined
associations was similar for G4965C, with ORs of 1.97 and 4.60 for variant (GC + CC)
genotype and exposure beyond the 75th percentile, respectively, and 8.75 for variant
genotype and high exposure combined. The combined effect of high arsenic exposure and
M287T (TC + CC) genotype was greater than additive, whereas for the combination of high
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arsenic and G4965C (GC + CC) the effect was approximately multiplicative. For both
polymorphisms, the separate effect of high exposure and the combined effect of high
exposure and variant genotype were statistically significant, although the 95% CIs were
wide as a result of small numbers (Figure 1).
DISCUSSION
We have recently reported that exposure to iAs in drinking water is associated with an
increased risk of diabetes among Zimapan and Lagunera residents; we have also found
positive correlation between DMAsIII concentration in urine and the diabetes indicators.17
Here, we provide evidence that individuals with the variant AS3MT/287T and 4965C
genotypes have higher levels of DMAsIII in urine. Our data show that these individuals also
have higher levels of 2HBG and FBG, and suggest they are more likely to be classified as
diabetic by common clinical criteria. Taken together, these findings suggest that carriers of
the 287T and 4965C variant genotypes are more likely to develop diabetes when exposed to
iAs, possibly due to enhanced production of its toxic metabolite, DMAsIII. Consistent with
the results in this study our recent data indicate that in vitro methylation of iAs by
recombinant AS3MT/287T produces significantly more DMAsIII than methylation by wild-
type AS3MT/287M.26
Strengths of this study include the analysis of unstable, but highly toxic, methylated trivalent
metabolites of iAs in freshly collected urines and the use of multiple criteria to classify
diabetes status. The setting in an area with moderately elevated levels of iAs in drinking
water (mean concentration 43 p.p.b.) can also be considered a strength in that most previous
studies have been conducted in areas with higher exposures, leaving open questions about
the effects of iAs at lower concentrations that are more typical of population exposures
throughout the world.
The cross-sectional design used in this study is commonplace in this area of research, but
nevertheless limits interpretation in several respects. Prevalent cases of diabetes may differ
from incident cases in clinical characteristics of the disease or in the metabolism of arsenic.
In addition, there are indications that iAs exposures may have changed recently due to
changes in water supply and consumption, but we did not have data to account for those
changes.17 Selective migration can also be a source of bias in cross-sectional studies and it is
common for men in the areas we studied to emigrate for work. The study population was
predominantly female as a result, but there is no reason to believe that men or women with
particular genotypes or exposures were more likely to leave the area.
Interpretation of the study results is also limited by the small number of diabetes cases
among people with variant genotypes. This resulted in wide confidence intervals for several
associations, particularly those related to gene–environment interactions.
Our study builds on the previous evidence linking iAs exposure to diabetes and is the first to
identify specific genotypes that can increase individual susceptibility to the diabetogenic
effects associated with this exposure.
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Interaction of wild-type and variant genotypes of M287T (circle) and G4965C (triangle)
polymorphisms and exposure to iAs in water categorized at the 75th percentile (52 p.p.b.).
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Table 1
Population characteristics and genotype frequencies.
N (mean) % (SD)
Population 255 100
Female 171 67
Age (years) (34) (18)
iAs concentration in drinking water (p.p.b.) (43) (48)
FBG (mg/dl) (92) (39)




    rs11191439
        TT 223 87
        CT 29 11
        CC 3 1
G35991A
    rs10748835
        GG 76 30
        GA 134 53
        AA 45 18
G12390C
    rs3740393
        GG 128 55
        GC 95 41
        CC 11 5
C14215T
    rs3740390
        CC 125 53
        CT 97 41
        TT 15 6
G4965C
    rs17881215
        GG 199 88
        GC 27 12
        CC 1 0
VNTR
        AB 173 72
        A2B 68 28
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Table 2
Association of the trivalent methylated metabolites of iAs and diabetes markers with genetic polymorphism.
Genotype
rs number










    TT (referent)
    TC/CC 0.11 (–0.22, 0.45) 0.47 (0.03, 0.91) 0.14 (0.01, 0.29) 0.19 (0.07, 0.31)
G35991A rs10748835
    AA/AG (referent)
    GG –0.16 (–0.41, 0.10) –0.21 (–0.53, 0.12) 0.03 ( –0.05, 0.13) –0.01 (–0.10, 0.08)
VNTR     AB (referent)
    A2B –0.16 (–0.43, 0.10) 0.04 (–0.31, 0.40) –0.01 (–0.11, 0.10) –0.04 (–0.14, 0.06)
G12390C rs3740393
    GG (referent)
    GC/CC –0.11 (–0.31, 0.10) –0.22 (–0.58, 0.15) –0.09 (–0.18, –0.01) –0.02 (–0.11, 0.06)
C14215T rs3740390
    CC (referent)
    CT/TT –0.09 (–0.30, 0.11) –0.31 (–0.68, 0.05) –0.08 (–0.16, 0.01) –0.06 (–0.15, 0.02)
G4965C rs17881215
    GG (referent)
    GC/CC 0.30 (–0.01, 0.61) 0.63 (0.07, 1.19) 0.19 (0.04, 0.33) 0.22 (0.09, 0.35)
Abbreviations: β, regression coefficient; CI, confidence interval.
a
Adjusted for age and sex.
b
Adjusted for age, sex, hypertension and obesity.
c
rs numbers were cited from NCBI SNP data base (http://www.ncbi.nlm.nih.gov/projects/SNP/).
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Table 3
Association of diabetes status classified by 2HBG ≥ 200mg/dl, FBG ≥ 126mg/dl or self-reported diagnosis or





    TT 17 206 1.00
    TC/CC 7 25 2.70 (0.93, 7.80)
G35991A
    AA/AG 17 162 1.00
    GG 7 69 0.92 (0.35, 2.42)
VNTR
    AB 17 157 1.00
    2AB 6 62 0.57 (0.20, 1.64)
G12390C
    GG 13 115 1.00
    GC/CC 8 98 0.82 (0.31, 2.17)
C14215T
    CC 14 111 1.00
    CT/TT 7 105 0.63 (0.23, 1.70)
G4965C
    GG 16 184 1.00
    GC/CC 6 22 2.24 (0.69, 7.25)
Abbreviations: CI, confidence interval; OR, odds ratio.
a
Adjusted for age, sex, hypertension and obesity.
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